Methods of treating alzheimer's disease

A technology for effective treatment and patient application in chemical instruments and methods, biochemical equipment and methods, pharmaceutical formulations, etc.

Inactive Publication Date: 2017-02-22
F HOFFMANN LA ROCHE & CO AG
View PDF93 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Currently approved therapies treat only some of the symptoms of AD, not the underlying regression

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods of treating alzheimer's disease
  • Methods of treating alzheimer's disease
  • Methods of treating alzheimer's disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0645] Example 1-Clinical study of creizumab (a humanized anti-Aβ monoclonal antibody) in the treatment of mild to moderate Alzheimer's disease

[0646] Research Design and Objectives

[0647] A randomized, double-blind, phase II trial was conducted using placebo-controlled to evaluate the use of the humanized monoclonal anti-amyloid beta ("Aβ") antibody creizumab in patients diagnosed with mild to moderate Alzheimer's disease. Effects in Patients with Murray's Disease (AD). Patients included in the study were between the ages of 50 and 80 at screening and had a diagnosis of probable AD according to the following NINCDS-ADRDA criteria: Mini-Mental State Examination (MMSE) score of 18 to 26 points, Geriatric Depression Scale (GDS-15) score less than 6, completion of 6 years of education (or excellent work history consistent with exclusion of mental retardation or other pervasive developmental disabilities). Additionally, for those patients receiving concurrent AD therapy (suc...

Embodiment 2

[0659] Example 2-Clinical study of creizumab (a humanized anti-Aβ monoclonal antibody) in the treatment of mild to moderate Alzheimer's disease and the impact on amyloid load

[0660] Research Design and Objectives

[0661] A randomized, double-blind, phase II trial was conducted using placebo-controlled to evaluate the use of the humanized monoclonal anti-amyloid beta ("Aβ") antibody creizumab in patients diagnosed with mild to moderate Alzheimer's disease. Effects in Patients with Murray's Disease (AD). Patients included in the study were between the ages of 50 and 80 at screening and had a diagnosis of probable AD according to the following NINCDS-ADRDA criteria: Mini-Mental State Examination (MMSE) score of 18 to 26 points, Geriatric Depression Scale (GDS-15) score less than 6, completion of 6 years of education (or excellent work history consistent with exclusion of mental retardation or other pervasive developmental disabilities). Only patients with positive florbetapi...

Embodiment 3

[0668] Example 3 - Monocytes associated with therapeutic response in the treatment of mild to moderate Alzheimer's disease in a clinical study of creizumab, a humanized anti-Aβ monoclonal antibody The study of nucleotide polymorphism

[0669] Research Design and Objectives

[0670] A randomized, double-blind, phase II trial was conducted using placebo-controlled to evaluate the use of the humanized monoclonal anti-amyloid beta ("Aβ") antibody creizumab in patients diagnosed with mild to moderate Alzheimer's disease. Effects in Patients with Murray's Disease (AD). Patients included in the study were between the ages of 50 and 80 at screening and had a diagnosis of probable AD according to the following NINCDS-ADRDA criteria: Mini-Mental State Examination (MMSE) score of 18 to 26 points, Geriatric Depression Scale (GDS-15) score less than 6, completion of 6 years of education (or excellent work history consistent with exclusion of mental retardation or other pervasive developm...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Methods of treating Alzheimer's Disease (AD) in patients suffering from mild to moderate AD, including ApoE4 positive patients and patients suffering from mild AD are provided. Also provided are methods of selecting or identifying patients for treatment with an anti-Abeta antibody. Methods include the use of prognostic and / or predictive biomarkers.

Description

[0001] Cross references to related applications [0002] This application claims U.S. Provisional Application No. 61 / 937,472 filed February 8, 2014, U.S. Provisional Application No. 61 / 971,499 filed March 27, 2014, U.S. Provisional Application No. 61 / 971,499 filed June 10, 2014 62 / 010,265, and the benefit of U.S. Provisional Application No. 62 / 082,013, filed November 19, 2014, the entire contents of which are incorporated herein by reference. [0003] field of invention [0004] Methods of treating patients with mild to moderate Alzheimer's disease using antibodies targeting amyloid beta are provided. Also provided are methods of selecting or identifying a patient for treatment with an antibody targeting amyloid beta. Methods include the use of prognostic and / or predictive biomarkers. [0005] Background of the invention [0006] Alzheimer's disease (AD) is the most common cause of dementia, affecting an estimated 4.5 million people in the United States and 26.6 million peop...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K39/00A61P25/28C07K16/18
CPCA61K2039/505C07K2317/24C07K2317/34C07K16/18A61P25/28A61K39/395C12Q1/6806C12Q1/6883C12Q2600/106C12Q2600/156C12Q2600/158
Inventor R·格雷汉姆
Owner F HOFFMANN LA ROCHE & CO AG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap